Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
Alessandro ConfortiSandro C EstevesPeter HumaidanSalvatore LongobardiThomas D'HoogheRaoul OrvietoAlberto VaiarelliDanilo CimadomoLaura RienziFilippo Maria UbaldiFulvio ZulloCarlo AlviggiPublished in: Reproductive biology and endocrinology : RB&E (2021)
Although more oocytes were retrieved in patients who underwent r-hFSH monotherapy, this meta-analysis suggests that r-hFSH/r-hLH co-treatment improves clinical pregnancy and implantation rates in women between 35 and 40 years of age undergoing ovarian stimulation for assisted reproduction technology. However, more RCTs using narrower age ranges in advanced age women are warranted to corroborate these findings.
Keyphrases
- systematic review
- polycystic ovary syndrome
- pregnancy outcomes
- recombinant human
- end stage renal disease
- combination therapy
- newly diagnosed
- ejection fraction
- cervical cancer screening
- pregnant women
- randomized controlled trial
- type diabetes
- peritoneal dialysis
- insulin resistance
- metabolic syndrome
- adipose tissue
- open label
- meta analyses
- patient reported